KappaMab Phase IIb
KappaMab is one of a new class of medicines called monoclonal antibodies under development for use in multiple myeloma.
Triplet therapy of cyclophosphamide, thalidomide and dexamethasone (CTD) is standard therapy for relapsed refractory multiple myeloma (RR MM).
Bortezomib, cyclophosphamide and dexamethasone (VCD) is the current standard of care in Australia for the initial treatment of transplant ineligible multiple myeloma patients.
V-VCD for transplant eligible myeloma
VCD (Bortezomib-cyclophosphamide, dexamethasone) is the current standard of care in Australia for the initial treatment of transplant eligible patients.
A stratified randomised controlled trial (the FRAIL-M study) will be conducted to identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status.
A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)